WO2004050842A3 - Atm kinase compositions and methods - Google Patents

Atm kinase compositions and methods Download PDF

Info

Publication number
WO2004050842A3
WO2004050842A3 PCT/US2003/038091 US0338091W WO2004050842A3 WO 2004050842 A3 WO2004050842 A3 WO 2004050842A3 US 0338091 W US0338091 W US 0338091W WO 2004050842 A3 WO2004050842 A3 WO 2004050842A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
atm
atm kinase
kinase
compositions
Prior art date
Application number
PCT/US2003/038091
Other languages
French (fr)
Other versions
WO2004050842A2 (en
Inventor
Michael B Kastan
Christopher J Bakkenist
Original Assignee
St Jude Childrens Res Hospital
Michael B Kastan
Christopher J Bakkenist
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/307,077 external-priority patent/US7108992B2/en
Application filed by St Jude Childrens Res Hospital, Michael B Kastan, Christopher J Bakkenist filed Critical St Jude Childrens Res Hospital
Priority to AU2003297595A priority Critical patent/AU2003297595A1/en
Publication of WO2004050842A2 publication Critical patent/WO2004050842A2/en
Publication of WO2004050842A3 publication Critical patent/WO2004050842A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides methods for detecting activation of ATM kinase, DNA damage, and DNA damaging agents. Further provided are antibodies which specifically recognize the phosphorylation state of Ataxia Telangiectasia-Mutated (ATM) kinase. Methods of identifying agents which modulate the activation and activity of ATM kinase are also provided.
PCT/US2003/038091 2002-11-27 2003-11-26 Atm kinase compositions and methods WO2004050842A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003297595A AU2003297595A1 (en) 2002-11-27 2003-11-26 Atm kinase compositions and methods

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/307,077 US7108992B2 (en) 2002-11-27 2002-11-27 ATM kinase compositions and methods
US10/307,077 2002-11-27
US10/351,733 US6916627B2 (en) 2002-11-27 2003-01-24 ATM kinase compositions and methods
US10/351,733 2003-01-24

Publications (2)

Publication Number Publication Date
WO2004050842A2 WO2004050842A2 (en) 2004-06-17
WO2004050842A3 true WO2004050842A3 (en) 2005-08-11

Family

ID=32474121

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2003/038091 WO2004050842A2 (en) 2002-11-27 2003-11-26 Atm kinase compositions and methods
PCT/US2003/037838 WO2004050837A2 (en) 2002-11-27 2003-11-26 Treatment of dna damage related disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2003/037838 WO2004050837A2 (en) 2002-11-27 2003-11-26 Treatment of dna damage related disorders

Country Status (3)

Country Link
US (7) US6916627B2 (en)
AU (2) AU2003293099A1 (en)
WO (2) WO2004050842A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
JP2007512378A (en) * 2003-11-26 2007-05-17 アークル インコーポレイテッド Use of β-lapachone to protect against radiation damage
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
EP1976566A4 (en) 2005-12-19 2010-10-20 Univ Northwestern Compositions and methods for altering rnai
EP1881080A1 (en) * 2006-07-18 2008-01-23 Institut Gustave Roussy Toll like receptor 4 dysfunction and the biological applications thereof
EP2156179B1 (en) * 2007-04-04 2021-08-18 The Regents of The University of California Methods for using a nanopore
WO2009047567A1 (en) * 2007-10-10 2009-04-16 University Of Sheffield Assay for identifying agents which inhibit the atr and/or dna-pk pathways
CA2703585A1 (en) 2007-10-23 2009-04-30 The Regents Of The University Of Colorado Competitive inhibitors of invariant chain expression and/or ectopic clip binding
WO2010008554A2 (en) * 2008-07-14 2010-01-21 The Regents Of The University Of Colorado Methods and products for treating proliferative diseases
US20120077843A1 (en) * 2009-03-30 2012-03-29 George Mason Intellectual Properties, Inc. Malignant precursor cells from ductal carcinoma in situ lesions
US8716307B2 (en) * 2009-05-13 2014-05-06 The Trustees Of The University Of Pennsylvania Combination antineoplastic therapy
KR101128058B1 (en) 2009-10-15 2012-04-12 한국원자력의학원 Composition comprising tolnaftate for inhibiting ATM kinase
CN106255883B (en) 2014-02-17 2019-10-08 克劳德贝尔纳里昂第一大学 Characterize the radiosensitivity of patient for treatment's property ionising radiation and the prediction technique of tissue reaction
CA3077028A1 (en) * 2017-09-25 2019-03-28 Justice E. OBI Compositions and methods for treatment of bowen's disease and related diseases
CN109797128A (en) * 2019-01-14 2019-05-24 浙江大学 A kind of construction method of acute cell iron overload model
CN112553274B (en) * 2020-12-02 2023-06-13 江南大学 Method for cutting DNA by soybean extract Bowman-Birk inhibitor
WO2023152668A1 (en) * 2022-02-14 2023-08-17 Università Degli Studi Di Urbino Carlo Bo Variants of the human atm protein for the treatment of diseases related to at least one mutation of the atm gene

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3127401A (en) * 1964-03-31 Z-benzyl-j
US2233970A (en) 1941-03-04 Quinoline compound and process of
NL130759C (en) * 1965-10-07
US3663693A (en) * 1967-03-16 1972-05-16 Sterling Drug Inc Antimalarial compositions and methods of their use
US3689646A (en) * 1969-09-04 1972-09-05 Univ Pennsylvania Antimutagenic treatment of bacteria
US4181725A (en) 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis
DE2748333A1 (en) 1977-10-28 1979-05-03 Hoechst Ag AGENT AGAINST MALARIA
US4431807A (en) 1980-06-12 1984-02-14 The United States Of America As Represented By The Secretary Of The Army 4-Methyl-5-(unsubstituted and substituted phenoxy)-6-methoxy-8-(aminoalkylamino)quinolines
FR2498187A1 (en) 1981-01-16 1982-07-23 Rhone Poulenc Sante PROCESS FOR THE PREPARATION OF AMINO-4 CHLORO-7 QUINOLINES
US5278173A (en) 1988-06-30 1994-01-11 Davis Michael H Method of inhibiting the activity of human immunodeficiency virus (HIV) in vivo
ZA899033B (en) 1988-12-01 1990-09-26 Merrell Dow Pharma Phenoxy and phenylthio,amino substituted benzocycloalkane derivatives in the treatment and prevention of drug-resistant protozoal infections
US5668149A (en) 1990-01-26 1997-09-16 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of human immunodeficiency virus-1 infectivity in human cells
US5242932A (en) 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
US5430039A (en) 1990-09-28 1995-07-04 Cephalon, Inc. Treatment of neurological disorders
ES2097905T3 (en) 1991-02-25 1997-04-16 Debiopharm Sa THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER MULTI-DRUG RESISTANCE.
MX9206309A (en) * 1991-11-04 1994-05-31 David Rubin METHOD AND COMPOSITION TO TREAT TUMORS THAT HAVE HIGH ACTIVITY OF THYROSINASE.
US5639737A (en) * 1991-11-04 1997-06-17 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
CA2117913C (en) 1992-04-10 2006-05-09 Richard J. Epstein Activation-state-specific phosphoprotein immunodetection
US5314894A (en) 1992-09-15 1994-05-24 Sterling Winthrop Inc. (S)-(+)-hydroxychloroquine
US5340603A (en) 1993-08-30 1994-08-23 Abbott Laboratories Nutritional product for human infants having chronic lung disease
CA2133620A1 (en) 1993-10-28 1995-04-29 Werner Hofheinz Aminoquinoline derivatives
US5639761A (en) 1994-02-14 1997-06-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antimalarial naphthylisoquinoline alkaloids and pharmaceutical compositions and medical uses thereof
US5665359A (en) * 1994-04-29 1997-09-09 Ho; Walter Kwok Keung Method and compositions for lowering blood lipids
US5624938A (en) 1994-07-18 1997-04-29 The Trustees Of Columbia University In The City Of New York Use of chloroquine to treat multiple sclerosis
PT876346E (en) 1995-11-16 2002-01-30 Hoffmann La Roche QUINOLINE DERIVATIVES WITH ANTI-MALARIA ACTIVITY
WO1998056391A1 (en) 1997-06-13 1998-12-17 President And Fellows Of Harvard College Methods for treating human cancers
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6348311B1 (en) 1999-02-10 2002-02-19 St. Jude Childre's Research Hospital ATM kinase modulation for screening and therapies
US6387640B1 (en) 1999-02-10 2002-05-14 St. Jude Children's Research Hospital ATM kinase modulation for screening and therapies
WO2001003649A2 (en) 1999-07-13 2001-01-18 Alpha Research Group, Llc Compositions and methods for the treatment of parkinson's disease
US6811788B2 (en) * 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
KR100390332B1 (en) 2000-08-02 2003-07-07 유원민 anti-cancer composition composed of anti-cancer and anti-malarial drugs
WO2002053138A2 (en) * 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US6579898B2 (en) 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
WO2002069949A2 (en) 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
CA2454643A1 (en) 2001-07-23 2003-02-20 Epidauros Biotechnologie Ag Methods for the treatment of cancer with irinotecan based on cyp3a5

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANMAN C.E. ET AL: "Activation of the ATM kinase by Ionizing radiation and phosphorylation of p53", SCIENCE, vol. 281, 11 September 1998 (1998-09-11), pages 1677 - 1679, XP002988744 *

Also Published As

Publication number Publication date
AU2003293099A1 (en) 2004-06-23
AU2003297595A1 (en) 2004-06-23
US20070009919A1 (en) 2007-01-11
US7160692B2 (en) 2007-01-09
US6916627B2 (en) 2005-07-12
US20060241139A1 (en) 2006-10-26
US20030157572A1 (en) 2003-08-21
US20090099134A1 (en) 2009-04-16
US20050032834A1 (en) 2005-02-10
US20050148020A1 (en) 2005-07-07
US7279290B2 (en) 2007-10-09
AU2003297595A8 (en) 2004-06-23
WO2004050837A3 (en) 2006-04-06
WO2004050842A2 (en) 2004-06-17
US20080020462A1 (en) 2008-01-24
AU2003293099A8 (en) 2004-06-23
WO2004050837A2 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
WO2004050842A3 (en) Atm kinase compositions and methods
WO1999054286A3 (en) Btk inhibitors and methods for their identification and use
WO2003066802A3 (en) Gene expression analysis using nicking agents
WO2005028443A3 (en) Protein tyrosine kinase enzyme inhibitors
IL170669A0 (en) Anaplastic lymphoma kinase assay, reagents and compositions thereof
WO2005014850A3 (en) Systems and methods for analyzing nucleic acid sequences
WO2004062475A3 (en) Fluorescent assays for protein kinases
WO2003016475A3 (en) Nucleic acid and amino acid sequences involved in pain
WO2006038208A3 (en) Agents capable of downregulating an msf-a - dependent hif-1α and use thereof in cancer treatment
WO2005042704A3 (en) Differential enzymatic fragmentation
WO2005012574A3 (en) Biological bar-code
WO2004069184A3 (en) Methods for treating, preventing and detecting helicobacter infection
WO2003050260A3 (en) Streptavidin expressed gene fusions and methods of use thereof
WO2005089505A3 (en) Detection, isolation and uses of renalase (monoamine oxidase c)
WO1999020747A3 (en) HUMAN CHECKPOINT KINASE, hCDS1, COMPOSITIONS AND METHODS
WO2002070541A3 (en) Peptide deformylase inhibitors
WO2001009384A3 (en) Serial analysis of genetic alterations
WO2005087932A3 (en) Vectors for directional cloning
WO2002101009A3 (en) Structural and cytoskeleton-associated proteins
WO2005026378A3 (en) Methods for gene function analysis
WO2002070540A3 (en) Peptide deformylase inhibitors
WO2005003388A3 (en) Fluorescence assays for nucleic acid polymerase activity
WO2001012838A3 (en) Compounds which modulate the activity of an lpa receptor
WO2002070653A3 (en) Peptide deformylase inhibitors
WO2003016549A3 (en) Nucleic-acid associated proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP